Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Banned Doping Substance Contamination on API Production Line: Sawai Report
Sawai Pharmaceutical submitted on April 19 the results of its investigation on the contamination of acetazolamide, a prohibited doping substances, in its GI drug Ecabet Na Granules 66.7% “Sawai” to the health minister, saying that the contamination happened on the…
To read the full story
Related Article
- Sawai Reaches Settlement over Doping Substance Contamination Lawsuit
March 18, 2021
- Sawai Recalls GI Drug after Doping Substance Found
March 6, 2019
BUSINESS
- Insilico, Takeda Ink AI Drug Discovery Deal Worth Up to US$600 Million
July 3, 2026
- Otsuka’s Voyxact Shows Two-Year Kidney Benefit in PIII IgAN Trial
July 3, 2026
- PeptiDream, NCC Start FIH Study of CLDN18.2 Radiopharmaceutical
July 3, 2026
- PeptiDream Poaches 3 EVPs to Bolster Global Expansion
July 3, 2026
- Eisai’s Dayvigo Accepted for UK Regulatory Review
July 3, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…